Dr Thomas Sandal | VP R&D
Crescendo Biologics Ltd

Dr Thomas Sandal, VP R&D, Crescendo Biologics Ltd

Thomas Sandal currently holds a position as VP R&D  at Crescendo Biologics. Thomas is a member of Crescendo Biologics’ executive team and responsible for managing preclinical development capabilities and therapeutic programmes from early discovery through to the clinic. Thomas has more than 25 years of experience within the Biotech and Biopharmaceutical industry mainly within CMC activities, product formatting, formulation and delivery, pharmacokinetics, production and toxicology. Previous to Crescendo, he was responsible for production and characterisation of anticailin products at Pieris AG. At Domantis (subsequently GSK) he managed Preclinical Development and GMP manufacture and was responsible for the advanced asset, an inhaled dAb (domain antibody fragment) in clinical trials for pulmonary disease. Previously Thomas held senior positions in Novozymes and Novo Nordisk, and was a co-founder of CMC Biologics.


EAC 2017 Day 2, Wednesday 1st November 2017 @ 11:25

Small is beautiful – Humabodies Drug Conjugates, HDC’s a real alternative to ADC’s

  • Crescendo is developing a pipeline of novel multifunctional Humabody® therapeutics demonstrating excitingly differentiated efficacy compared with clinical mAbs
  • Optimally configured Humabody Drug Conjugates (HDCs) engage therapeutically valuable targets in a way that is different from whole antibodies, unlocking superior therapeutic index
  • Highly potent HDCs will play an important role in the next generation of targeted oncology therapeutics as a critical component of increasingly effective combination regimes

back to speakers